Bone turnover is altered in transgenic rats overexpressing the P2Y2 purinergic receptor
- PMID: 28828576
- PMCID: PMC5714845
- DOI: 10.1007/s11302-017-9582-3
Bone turnover is altered in transgenic rats overexpressing the P2Y2 purinergic receptor
Abstract
It is now widely recognized that purinergic signaling plays an important role in the regulation of bone remodeling. One receptor subtype, which has been suggested to be involved in this regulation, is the P2Y2 receptor (P2Y2R). In the present study, we investigated the effect of P2Y2R overexpression on bone status and bone cell function using a transgenic rat. Three-month-old female transgenic Sprague Dawley rats overexpressing P2Y2R (P2Y2R-Tg) showed higher bone strength of the femoral neck. Histomorphometry showed increase in resorptive surfaces and reduction in mineralizing surfaces. Both mineral apposition rate and thickness of the endocortical osteoid layer were higher in the P2Y2R-Tg rats. μCT analysis showed reduced trabecular thickness and structural model index in P2Y2R-Tg rats. Femoral length was increased in the P2Y2R-Tg rats compared to Wt rats. In vitro, there was an increased formation of osteoclasts, but no change in total resorption in cultures from P2Y2R-Tg rats. The formation of mineralized nodules was significantly reduced in the osteoblastic cultures from P2Y2R-Tg rats. In conclusion, our study suggests that P2Y2R is involved in regulation of bone turnover, due to the effects on both osteoblasts and osteoclasts and that these effects might be relevant in the regulation of bone growth.
Keywords: Cell/tissue signaling; Genetic animal models; Osteoblasts; Osteoclasts; P2Y2 purinergic receptors.
Conflict of interest statement
Ethical approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.
Conflict of interest
Maria Ellegaard declares that she has no conflict of interest.
Cansu Agca declares that she has no conflict of interest.
Solveig Petersen declares that she has no conflict of interest.
Ankita Agrawal declares that she has no conflict of interest.
Lars Schack Kruse declares that he has no conflict of interest.
Ning Wang declares that he/she has no conflict of interest.
Alison Gartland declares that she has no conflict of interest.
Jens-Erik Beck Jensen declares that he has no conflict of interest.
Niklas Rye Jørgensen declares that he has no conflict of interest.
Yuksel Agca declares that he has no conflict of interest.
Figures





References
-
- Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413–492. - PubMed
-
- Bowler WB, Dixon CJ, Halleux C, Maier R, Bilbe G, Fraser WD, Gallagher JA, Hipskind RA. Signaling in human osteoblasts by extracellular nucleotides. Their weak induction of the c-fos proto-oncogene via Ca2+ mobilization is strongly potentiated by a parathyroid hormone/cAMP-dependent protein kinase pathway independently of mitogen-activated protein kinase. J Biol Chem. 1999;274:14315–14324. doi: 10.1074/jbc.274.20.14315. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous